Vanguard Capital Management
CAI

Vanguard Capital Management’s Caris Life Sciences CAI Stock Holding History

Vanguard Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.3M Buy
4,280,238
+951,217
+29% +$17M ﹤0.01% 1704
2026
Q1 		$59.5M Buy
+3,329,021
New +$72.8M ﹤0.01% 1766

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management's CAI Position: Q2 2026 in Review

Vanguard Capital Management increased its Caris Life Sciences (CAI) stake by 29% in Q2 2026, buying an estimated $17M and bringing the position to 4,280,238 shares worth $76.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1704.

Vanguard Capital Management first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Vanguard Capital Management held 4,280,238 shares of Caris Life Sciences worth $76.3M as of Q2 2026.
  • Vanguard Capital Management bought 951,217 Caris Life Sciences shares in Q2 2026, an estimated $17M.
  • Caris Life Sciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1704 holding.
  • Vanguard Capital Management first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.